Isoniazid-Induced_NP Transient_NP High-Level_NP Resistance_NP in_IN Mycobacterium_NP tuberculosis_NN An_DT American_NP Type_NP Culture_NP Collection_NP reference_NN strain_NN and_CC eight_CD clinical_JJ strains_NNS of_IN Mycobacterium_NN tuberculosis_NN ,_, all_DT of_IN which_WDT were_VBD susceptible_JJ to_TO isoniazid_NN (_( INH_NP )_) (_( mean_VB MIC_JJ ,_, 0.06_CD mg/liter_NN )_) and_CC negative_JJ for_IN the_DT Ser315Thr_NP katG_NN mutation_NN ,_, were_VBD left_VBN in_IN their_PP$ BACTEC_NP 12B_JJ vials_NNS (_( for_IN use_NN with_IN the_DT BACTEC_NP 460-TB_JJ method_NN )_) containing_VBG 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN for_IN periods_NNS of_IN up_IN to_TO 28_CD days_NNS after_IN the_DT completion_NN of_IN the_DT antibiotic_JJ susceptibility_NN test_NN ._SENT Each_DT eventually_RB grew_VBN to_TO levels_NNS compatible_JJ with_IN those_DT of_IN INH-resistant_JJ strains_NNS ._SENT Successive_JJ passages_NNS in_IN INH-containing_NP BACTEC_NP 12B_NP vials_NNS and_CC onto_IN solid_JJ media_NNS showed_VBD that_IN the_DT resistance_NN noted_VBD above_IN was_VBD maintained_VBN ._SENT Successive_JJ passages_NNS of_IN these_DT M._NP tuberculosis_NN strains_NNS in_IN which_WDT INH_NP resistance_NN had_VBD been_VBN induced_VBN into_IN BACTEC_NP 12B_NP vials_NNS or_CC solid_JJ media_NNS containing_VBG stepwise_JJ increases_NNS in_IN INH_NP concentrations_NNS eventually_RB yielded_VBD organisms_NNS resistant_JJ to_TO 20_CD mg_NN of_IN INH_NP per_IN liter_NN ._SENT Transfer_NN of_IN cells_NNS in_IN which_WDT INH_NP resistance_NN had_VBD been_VBN induced_VBN to_TO drug-free_JJ medium_NN followed_VBN by_IN repeated_JJ passages_NNS in_IN that_DT medium_NN eventually_RB yielded_VBN organisms_NNS whose_WP$ susceptibility_NN to_TO INH_NP was_VBD identical_JJ to_TO that_DT of_IN the_DT original_JJ parent_NN strains_NNS ._SENT The_DT cycle_NN of_IN induced_VBN INH_NP resistance_NN could_MD be_VB repeated_VBN with_IN these_DT now_RB INH-susceptible_JJ cells_NNS ._SENT The_DT use_NN of_IN M._NP tuberculosis_NN identification_NN probes_NNS and_CC IS6110-based_JJ restriction_NN fragment_NN length_NN polymorphism_NN analyses_NNS of_IN cultures_NNS throughout_IN the_DT induction_NN of_IN INH_NP resistance_NN and_CC the_DT reversal_NN of_IN resistance_NN in_IN drug-free_JJ medium_NN eliminated_VBD the_DT possibility_NN that_IN the_DT culture_NN was_VBD contaminated_VBN or_CC that_IN the_DT initial_JJ specimen_NN had_VBD a_DT mixed_JJ type_NN of_IN infection_NN ._SENT Induced_VBN high-level_JJ resistance_NN to_TO INH_NP (_( 20_CD mg/liter_NN )_) could_MD be_VB reduced_VBN 100-fold_NN with_IN a_DT subinhibitory_JJ concentration_NN of_IN reserpine_NN but_CC not_RB with_IN verapamil_NN ._SENT These_DT results_NNS collectively_RB suggest_VBP that_IN high-level_JJ resistance_NN to_TO INH_NP can_MD be_VB induced_VBN in_IN INH-susceptible_NP M._NP tuberculosis_NN strains_NNS by_IN the_DT induction_NN of_IN a_DT reserpine-sensitive_JJ efflux_NN mechanism_NN ._SENT Isoniazid_NN (_( INH_NP )_) is_VBZ highly_RB effective_JJ against_IN Mycobacterium_NN tuberculosis_NN ,_, having_VBG MICs_NNS that_WDT range_VBP from_IN 0.02_CD to_TO 0.06_CD mg/liter_NN ._SENT However_RB ,_, the_DT rates_NNS of_IN resistance_NN to_TO INH_NP have_VBP been_VBN escalating_VBG worldwide_RB ._SENT The_DT mechanism_NN by_IN which_WDT the_DT resistance_NN of_IN M._NP tuberculosis_NN to_TO INH_NP takes_VBZ place_NN is_VBZ very_RB complex_JJ and_CC has_VBZ been_VBN ascribed_VBN to_TO the_DT individual_JJ mutation_NN of_IN genes_NNS encoding_VBG a_DT catalase-peroxidase_NN (_( katG_NN )_) ,_, an_DT enzyme_NN of_IN the_DT mycolic_JJ acid_NN pathway_NN (_( inhA_NN )_) ,_, and_CC a_DT beta-ketoacyl-acyl_NN carrier_NN protein_NN synthetase_NN (_( kasA_NN )_) ._SENT Because_IN only_RB about_RB 50_CD to_TO 60_CD %_NN of_IN all_DT strains_NNS studied_VBD so_RB far_RB have_VB mutations_NNS in_IN any_DT of_IN these_DT genes_NNS associated_VBN with_IN resistance_NN to_TO INH_NP ,_, conventional_JJ wisdom_NN dictates_VBZ that_IN other_JJ genetic_JJ factors_NNS bestowing_VBG resistance_NN to_TO INH_NP must_MD be_VB involved_VBN ._SENT To_TO this_DT extent_NN ,_, resistance_NN to_TO INH_NP has_VBZ also_RB been_VBN related_VBN to_TO its_PP$ neutralization_NN by_IN the_DT overproduction_NN of_IN arylamine_NN N-acetyltransferase_NN ,_, by_IN limitations_NNS of_IN NAD+-binding_JJ proteins_NNS ,_, and_CC by_IN the_DT overexpression_NN of_IN antioxidant_NN enzymes_NNS that_WDT compensate_VBP for_IN the_DT loss_NN of_IN function_NN of_IN the_DT KatG_NP protein_NN ._SENT The_DT first_JJ and_CC last_JJ mechanisms_NNS still_RB fail_VBP to_TO account_VB for_IN the_DT resistance_NN in_IN at_IN least_JJS 20_CD %_NN of_IN all_DT INH-resistant_JJ strains_NNS ._SENT Plasmids_NNS play_VBP no_DT role_NN in_IN acquired_JJ INH_NP resistance_NN in_IN M._NP tuberculosis_NN ._SENT Resistance_NN to_TO INH_NP is_VBZ not_RB totally_RB accounted_VBN for_IN by_IN the_DT mechanisms_NNS described_VBD above_IN ,_, since_IN recent_JJ evidence_NN shows_VBZ that_DT resistance_NN to_TO INH_NP in_IN Mycobacterium_NP smegmatis_NN can_MD also_RB be_VB mediated_VBN by_IN an_DT energy-dependent_JJ efflux_NN pump_NN ._SENT Efflux_NN pumps_NNS that_WDT render_VBP an_DT organism_NN resistant_NN to_TO one_CD or_CC more_JJR antibiotics_NNS have_VBP been_VBN identified_VBN in_IN all_DT bacteria_NNS that_WDT have_VBP been_VBN subjected_VBN to_TO such_JJ analyses_NNS ,_, including_VBG mycobacteria_NNS ._SENT These_DT pumps_NNS are_VBP normally_RB present_JJ in_IN the_DT plasma_NN membrane_NN of_IN the_DT bacterium_NN and_CC afford_VB protection_NN from_IN toxic_JJ substances_NNS that_WDT are_VBP recognized_VBN as_IN substrates_NNS by_IN the_DT pump_NN ._SENT Susceptibility_NN to_TO a_DT given_VBN antibiotic_NN that_WDT is_VBZ a_DT coincidental_JJ substrate_NN for_IN a_DT pump_NN may_MD be_VB considered_VBN the_DT result_NN of_IN overcoming_VBG the_DT effectiveness_NN of_IN the_DT pump_NN due_JJ to_TO its_PP$ limited_JJ number_NN of_IN units_NNS ._SENT Because_IN among_IN the_DT isolates_NNS of_IN one_PP strain_VBP there_EX are_VBP members_NNS that_WDT have_VBP different_JJ quantitative_JJ susceptibilities_NNS to_TO a_DT given_VBN antibiotic_NN attributed_VBD to_TO genotypic_JJ variation_NN ,_, it_PP is_VBZ possible_JJ that_IN these_DT differences_NNS may_MD be_VB due_JJ to_TO a_DT variation_NN in_IN the_DT number_NN of_IN existing_VBG efflux_NN pumps_NNS ._SENT Furthermore_RB ,_, these_DT variations_NNS may_MD be_VB due_JJ to_TO a_DT mechanism_NN that_WDT controls_VBZ the_DT number_NN of_IN such_JJ pump_NN units_NNS ._SENT The_DT demonstration_NN of_IN antibiotic_JJ efflux_NN pumps_NNS in_IN mycobacteria_NNS has_VBZ raised_VBN the_DT obvious_JJ question_NN of_IN whether_IN these_DT or_CC any_DT antibiotic_JJ efflux_NN pump_NN is_VBZ subject_JJ to_TO an_DT increase_NN in_IN their_PP$ number_NN ,_, which_WDT in_IN turn_NN renders_VBZ the_DT organism_NN increasingly_RB resistant_JJ to_TO the_DT antibiotic_NN ._SENT To_TO this_DT extent_NN we_PP have_VBP attempted_VBN and_CC succeeded_VBN to_TO induce_VB INH_NP sensitivity_NN in_IN M._NP tuberculosis_NN strains_NNS increasingly_RB resistant_JJ to_TO INH_NP by_IN mechanisms_NNS that_WDT do_VBP not_RB involve_VB the_DT selection_NN of_IN mutations_NNS that_WDT bestow_VBP resistance_NN to_TO this_DT antibiotic_NN ._SENT The_DT mechanism_NN by_IN which_WDT this_DT induced_VBN resistance_NN to_TO INH_NP takes_VBZ place_NN might_MD involve_VB an_DT efflux_NN pump_NN ._SENT Antibiotics_NNS and_CC chemicals_NNS ._SENT |_SYM INH_NP ,_, chlorpromazine_NN (_( CPZ_NP )_) ,_, verapamil_NN ,_, and_CC reserpine_NN were_VBD purchased_VBN from_IN Sigma_NP Aldrich_NP Quimica_NP SA_NP ,_, Madrid_NP ,_, Spain_NP ._SENT Rifampin_NP ,_, streptomycin_NN ,_, and_CC ethambutol_NN as_RB well_RB as_IN all_DT materials_NNS and_CC equipment_NN used_VBN to_TO test_VB the_DT antibiotic_JJ susceptibilities_NNS of_IN the_DT M._NP tuberculosis_NN strains_NNS tested_VBN with_IN the_DT BACTEC_NP 460-TB_JJ system_NN were_VBD purchased_VBN from_IN Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NP ,_, Sparks_NP ,_, Md._NP ,_, and_CC were_VBD prepared_VBN according_VBG to_TO the_DT recommendations_NNS of_IN the_DT manufacturer_NN ._SENT Solid_JJ and_CC liquid_JJ media_NNS used_VBN for_IN purposes_NNS other_JJ than_IN susceptibility_NN testing_NN are_VBP identified_VBN in_IN the_DT legends_NNS to_TO the_DT figures_NNS or_CC in_IN the_DT tables_NNS and_CC were_VBD purchased_VBN from_IN Difco_NP ,_, Detroit_NP ,_, Mich._NP All_NP solutions_NNS were_VBD freshly_RB prepared_VBN on_IN the_DT day_NN of_IN any_DT given_VBN experiment_NN ._SENT Microorganisms_NNS ._SENT |_SYM M._NP tuberculosis_NN H37Rv_NP (_( strain_NN ATCC_NP 27294_CD from_IN the_DT American_NP Type_NP Culture_NP Collection_NP (_( [_SYM ATCC_NP ]_SYM )_) and_CC eight_CD clinical_JJ isolates_NNS of_IN M._NP tuberculosis_NN ,_, the_DT latter_NN of_IN which_WDT were_VBD isolated_VBN from_IN untreated_JJ patients_NNS and_CC previously_RB shown_VBN to_TO be_VB susceptible_JJ to_TO INH_NP ,_, rifampin_NN ,_, streptomycin_NN ,_, and_CC ethambutol_NN by_IN the_DT BACTEC_NP 460-TB_JJ system_NN (_( S._NP Siddiqi_NP ,_, BACTEC_NP TB_NN system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, 1980_CD ,_, Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NP ,_, Towson_NP ,_, Md._NP )_) ,_, were_VBD selected_VBN for_IN this_DT study_NN and_CC were_VBD designated_VBN INH-susceptible_JJ strains_NNS ._SENT Drug_NN susceptibility_NN assays_NNS by_IN the_DT BACTEC_NP 460-TB_JJ radiometric_JJ proportion_NN method_NN and_CC determination_NN of_IN INH_NP MICs_NP by_IN the_DT broth_NN (_( BACTEC_NP )_) radiometric_JJ method_NN and_CC the_DT agar_NN dilution_NN method_NN ._SENT |_SYM The_DT indirect_JJ drug_NN susceptibility_NN assay_NN (_( the_DT BACTEC_NP 460-TB_JJ radiometric_JJ proportion_NN method_NN )_) was_VBD conducted_VBN with_IN the_DT respective_JJ desired_VBN final_JJ concentrations_NNS of_IN INH_NP (_( 0.1_CD mg/liter_NN )_) ,_, rifampin_NN (_( 2_CD mg/liter_NN )_) ,_, streptomycin_NN (_( 6_CD mg/liter_NN )_) ,_, and_CC ethambutol_NN (_( 7.5_CD mg/liter_NN )_) by_IN the_DT procedure_NN and_CC with_IN the_DT interpretive_JJ criteria_NNS recommended_VBN by_IN the_DT manufacturer_NN (_( ;_: S._NP Siddiqi_NP ,_, BACTEC_NP TB_NN system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NPS )_) and_CC by_IN Rastogi_NP et_FW al._FW ._SENT Absolute_JJ control_NN vials_NNS (_( with_IN no_DT drug_NN )_) and_CC drug-containing_NN vials_NNS were_VBD inoculated_VBN with_IN approximately_RB 105_CD to_TO 106_CD CFU_NN of_IN an_DT organism_NN identified_VBN as_IN M._NP tuberculosis_NN by_IN rRNA-DNA_NN probe_NN hybridization_NN (_( AccuProbe_NP ;_: Gen-Probe-BioMerieux_NP ,_, Lyon_NP ,_, France_NP )_) ._SENT A_DT separate_JJ 1/100_CD dilution_NN of_IN each_DT bacterial_JJ suspension_NN served_VBN as_IN the_DT proportional_JJ control_NN ._SENT All_DT vials_NNS were_VBD incubated_VBN at_IN 37C_NP and_CC were_VBD evaluated_VBN daily_RB until_IN the_DT growth_NN index_NN of_IN the_DT proportional_JJ control_NN reached_VBD 30_CD ,_, which_WDT was_VBD within_IN 4_CD to_TO 12_CD days_NNS ._SENT The_DT MIC_NP of_IN INH_NP was_VBD determined_VBN for_IN the_DT H37Rv_NP (_( ATCC_NP 27294_CD )_) control_NN strain_NN and_CC clinical_JJ strains_NNS by_IN the_DT modified_JJ broth_NN radiometric_JJ method_NN of_IN Lee_NP and_CC Heifets_NP (_( ;_: S._NP Siddiqi_NP ,_, BACTEC_NP TB_NN system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NPS )_) ._SENT The_DT MIC_NN was_VBD defined_VBN as_IN the_DT lowest_JJS INH_NP concentration_NN that_WDT completely_RB inhibited_VBD the_DT generation_NN of_IN 14CO2_JJ after_IN an_DT incubation_NN period_NN of_IN 12_CD days_NNS ._SENT The_DT determination_NN of_IN the_DT INH_NP MIC_NP by_IN the_DT agar_NN dilution_NN method_NN was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT The_DT simultaneous_JJ use_NN of_IN Middlebrook_NP 7H11_JJ solid_JJ medium_NN for_IN susceptibility_NN testing_NN and_CC MIC_JJ determination_NN was_VBD necessary_JJ because_IN the_DT agar_NN dilution_NN method_NN ,_, the_DT "_`` gold_JJ standard_NN "_'' in_IN mycobacteriology_NN ,_, affords_VBZ accurate_JJ determination_NN of_IN the_DT percentage_NN of_IN resistant_JJ bacteria_NNS in_IN the_DT population_NN present_NN in_IN the_DT broth_NN used_VBN by_IN the_DT radiometric_JJ method_NN as_IN well_RB as_RB for_IN the_DT isolation_NN of_IN single_JJ colonies_NNS ._SENT Both_DT methods_NNS yielded_VBD comparable_JJ MICs_NNS ._SENT Inducement_NN of_IN INH_NP resistance_NN ,_, reversal_NN of_IN resistance_NN ,_, and_CC repetition_NN of_IN the_DT cycle_NN of_IN INH-induced_JJ resistance_NN ._SENT |_SYM The_DT vials_NNS that_WDT were_VBD used_VBN to_TO determine_VB the_DT susceptibilities_NNS of_IN the_DT clinical_JJ and_CC INH-susceptible_JJ (_( ATCC_NP 27294_CD )_) strains_NNS to_TO INH_NP (_( 0.1_CD mg/liter_NN )_) and_CC that_DT would_MD normally_RB be_VB discarded_VBN after_IN a_DT maximum_NN of_IN 12_CD days_NNS (_( S._NP Siddiqi_NP ,_, BACTEC_NP TB_NN system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NP )_) were_VBD retained_VBN in_IN the_DT incubator_NN for_IN an_DT additional_JJ period_NN of_IN time_NN ._SENT By_IN the_DT end_NN of_IN 28_CD days_NNS ,_, all_RB of_IN the_DT vials_NNS yielded_VBD visible_JJ and_CC radiometric_JJ evidence_NN of_IN growth_NN ._SENT The_DT contents_NNS of_IN these_DT vials_NNS were_VBD identified_VBN as_IN M._NP tuberculosis_NN by_IN conventional_JJ biochemical_JJ methods_NNS and_CC rRNA-DNA_NN probe_NN hybridization_NN and_CC were_VBD evaluated_VBN for_IN INH_NP susceptibility_NN by_IN the_DT BACTEC_NP 460-TB_JJ and_CC solid_JJ medium_JJ methods_NNS ._SENT IS6110-based_JJ restriction_NN fragment_NN length_NN polymorphism_NN (_( RFLP_NP )_) analysis_NN (_( IS6110-RFLP_NP analysis_NN )_) confirmed_VBD that_IN each_DT of_IN the_DT bacterial_JJ populations_NNS that_WDT could_MD now_RB grow_VB in_IN the_DT presence_NN of_IN 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN was_VBD identical_JJ to_TO the_DT initial_JJ parent_NN population_NN ._SENT The_DT MIC_NP of_IN INH_NP for_IN each_DT of_IN these_DT strains_NNS was_VBD determined_VBN and_CC compared_VBN to_TO that_DT of_IN the_DT initial_JJ respective_JJ parent_NN ,_, and_CC aliquots_NNS of_IN 0.1_CD ml_NN from_IN growing_VBG cultures_NNS containing_VBG a_DT concentration_NN of_IN INH_NP just_RB below_IN the_DT MIC_NN were_VBD inoculated_VBN into_IN fresh_JJ BACTEC_NP 12B_JJ vials_NNS containing_VBG the_DT lowest_JJS INH_NP concentration_NN that_WDT had_VBD completely_RB inhibited_VBN the_DT growth_NN of_IN the_DT previous_JJ population_NN ._SENT At_IN the_DT end_NN of_IN 10_CD to_TO 28_CD days_NNS these_DT vials_NNS showed_VBD evidence_NN of_IN maximum_JJ growth_NN ,_, and_CC a_DT new_JJ INH_NP susceptibility_NN test_NN and_CC MIC_JJ determination_NN confirmed_VBD their_PP$ capacity_NN to_TO grow_VB in_IN the_DT presence_NN of_IN higher_JJR concentrations_NNS of_IN INH_NP that_WDT had_VBD previously_RB been_VBN shown_VBN to_TO inhibit_VB growth_NN ._SENT This_DT sequential_JJ process_NN was_VBD conducted_VBN for_IN five_CD additional_JJ consecutive_JJ passages_NNS ,_, with_IN each_DT passage_NN containing_VBG a_DT stepwise_JJ increase_NN in_IN the_DT concentration_NN of_IN INH_NP corresponding_JJ to_TO the_DT lowest_JJS concentration_NN that_WDT had_VBD inhibited_VBN growth_NN in_IN the_DT previous_JJ passage_NN ._SENT This_DT process_NN was_VBD conducted_VBN in_IN parallel_NN with_IN solid_JJ medium_NN ._SENT The_DT latter_JJ method_NN provided_VBD colonies_NNS that_WDT could_MD be_VB assayed_VBN for_IN identity_NN and_CC antibiotic_JJ susceptibility_NN and_CC colonies_NNS that_WDT could_MD be_VB assayed_VBN by_IN other_JJ procedures_NNS to_TO ensure_VB that_IN what_WP was_VBD being_VBG observed_VBN with_IN liquid_JJ medium_NN was_VBD also_RB taking_VBG place_NN in_IN solid_JJ medium_NN ._SENT This_DT phase_NN of_IN the_DT study_NN consumed_VBD an_DT average_NN of_IN 230_CD days_NNS (_( see_VB Fig._NN )_) with_IN the_DT radiometric_JJ broth_NN medium_NN and_CC yielded_VBD M._NP tuberculosis_NN isolates_NNS that_WDT were_VBD capable_JJ of_IN growing_VBG in_IN medium_NN containing_VBG a_DT concentration_NN of_IN INH_NP as_IN high_JJ as_IN 20_CD mg/liter_NN ._SENT The_DT potency_NN of_IN the_DT INH_NP in_IN the_DT medium_NN was_VBD assayed_VBN throughout_IN the_DT period_NN described_VBD above_IN after_IN the_DT removal_NN of_IN mycobacteria_NNS by_IN filtration_NN (_( filter_NN pore_NN size_NN ,_, 0.22_CD mum_NN ;_: Millipore_NP )_) ,_, and_CC the_DT cell-free_JJ medium_NN was_VBD reinoculated_VBN with_IN the_DT control_NN strain_NN ,_, H37Rv_NP (_( ATCC_NP 27294_CD )_) ._SENT After_IN the_DT sixth_JJ passage_NN (_( when_WRB the_DT strains_NNS were_VBD growing_VBG in_IN INH_NP at_IN 20_CD mg/liter_NN )_) ,_, each_DT derived_VBN INH-resistant_NP M._NP tuberculosis_NN isolate_NN obtained_VBN from_IN the_DT initially_RB INH-susceptible_JJ strains_NNS was_VBD subsequently_RB transferred_VBN to_TO INH-free_JJ medium_NN and_CC incubated_VBN for_IN an_DT extended_JJ period_NN of_IN 28_CD days_NNS ._SENT An_DT aliquot_NN from_IN each_DT vial_NN was_VBD then_RB transferred_VBN to_TO fresh_JJ INH-free_JJ medium_NN ,_, and_CC these_DT vials_NNS were_VBD reincubated_VBN for_IN the_DT same_JJ extended_JJ period_NN ;_: three_CD more_JJR consecutive_JJ passages_NNS in_IN drug-free_JJ medium_NN were_VBD conducted_VBN for_IN each_DT derived_VBN strain_NN ._SENT The_DT INH_NP MIC_NP for_IN each_DT strain_NN was_VBD determined_VBN after_IN each_DT passage_NN in_IN drug-free_JJ medium_NN ._SENT After_IN the_DT fourth_JJ passage_NN the_DT susceptibility_NN testing_NN criteria_NNS for_IN INH_NP susceptibility_NN were_VBD verified_VBN by_IN procedures_NNS conducted_VBN with_IN broth_NN and_CC solid_JJ media_NNS ._SENT Aliquots_NNS from_IN the_DT last_JJ passage_NN in_IN drug-free_JJ medium_NN were_VBD subjected_VBN to_TO the_DT same_JJ antibiotic_JJ susceptibility_NN assay_NN described_VBD above_IN for_IN the_DT respective_JJ initial_JJ strains_NNS ;_: i.e._FW ,_, they_PP were_VBD allowed_VBN to_TO remain_VB in_IN the_DT incubator_NN well_RB past_IN their_PP$ period_NN of_IN antibiotic_JJ susceptibility_NN until_IN evidence_NN of_IN growth_NN ._SENT The_DT contents_NNS were_VBD subjected_VBN to_TO the_DT same_JJ procedures_NNS used_VBN for_IN the_DT eventual_JJ inducement_NN of_IN high-level_JJ resistance_NN to_TO INH_NP described_VBD above_IN ._SENT IS6110-RFLP_NN analysis_NN and_CC analysis_NN of_IN katG_NN mutations_NNS by_IN PCR-RFLP_NP analysis_NN ._SENT |_SYM Before_IN and_CC after_IN the_DT inducement_NN of_IN resistance_NN to_TO INH_NP ,_, strain_NN H37Rv_NP (_( ATCC_NP 27294_CD )_) and_CC the_DT clinical_JJ strains_NNS were_VBD subjected_VBN to_TO IS6110-RFLP_NP analysis_NN to_TO determine_VB possible_JJ contamination_NN or_CC to_TO detect_VB an_DT initial_JJ mixed_JJ culture_NN ,_, as_RB described_VBN previously_RB ._SENT Determination_NN of_IN the_DT most_RBS common_JJ point_NN mutation_NN in_IN katG_NN ,_, consistently_RB found_VBN at_IN position_NN 315_CD (_( serine_NN to_TO threonine_NN [_SYM S315->T_NP ]_SYM )_) in_IN clinical_JJ isolates_NNS with_IN high-level_JJ INH_NP resistance_NN ,_, was_VBD conducted_VBN with_IN the_DT initial_JJ ATCC_NP control_NN strain_NN ,_, representatives_NNS of_IN the_DT initial_JJ INH-susceptible_JJ clinical_JJ strains_NNS ,_, representatives_NNS of_IN the_DT progeny_NN in_IN which_WDT INH_NP resistance_NN had_VBD been_VBN induced_VBN and_CC obtained_VBN after_IN the_DT sixth_JJ consecutive_JJ passage_NN in_IN INH_NP ,_, and_CC representatives_NNS obtained_VBN from_IN the_DT last_JJ (_( fourth_JJ )_) consecutive_JJ passage_NN in_IN the_DT absence_NN of_IN INH_NP ,_, as_RB described_VBN previously_RB ._SENT Two_CD mutants_NNS previously_RB found_VBD to_TO have_VB katG_NN mutations_NNS were_VBD similarly_RB analyzed_VBN and_CC served_VBN as_IN positive_JJ controls_NNS ._SENT MICs_NNS of_IN putative_JJ inhibitors_NNS of_IN efflux_NN pumps_NNS for_IN the_DT strains_NNS of_IN M._NP tuberculosis_NN used_VBN in_IN this_DT study_NN and_CC effects_NNS of_IN the_DT inhibitors_NNS on_IN induced_VBN INH_NP resistance_NN ._SENT |_SYM The_DT MICs_NP of_IN CPZ_NP ,_, verapamil_NN ,_, and_CC reserpine_NN for_IN strain_NN ATTC_NP 27294_CD and_CC the_DT clinical_JJ strains_NNS of_IN M._NP tuberculosis_NN were_VBD determined_VBN with_IN the_DT BACTEC_NP 460-TB_JJ system_NN described_VBN above_IN ,_, except_IN that_WDT INH_NP was_VBD replaced_VBN by_IN separate_JJ various_JJ concentrations_NNS of_IN known_VBN inhibitors_NNS of_IN efflux_NN pumps_NNS :_: CPZ_NN at_IN 1.25_CD to_TO 40_CD mg/liter_NN ,_, verapamil_NN at_IN 8_CD to_TO 5,000_CD mg/liter_NN ,_, and_CC reserpine_NN at_IN 0.01_CD to_TO 160_CD mg/liter_NN ._SENT These_DT inhibitors_NNS of_IN efflux_NN pumps_NNS were_VBD separately_RB added_VBN to_TO cultures_NNS at_IN concentrations_NNS that_WDT were_VBD previously_RB shown_VBN to_TO have_VB no_DT effect_NN on_IN the_DT growth_NN of_IN the_DT initial_JJ ATCC_NN and_CC clinical_JJ strains_NNS of_IN M._NP tuberculosis_NN used_VBN in_IN this_DT study_NN ._SENT The_DT concentrations_NNS of_IN these_DT compounds_NNS used_VBN in_IN combination_NN with_IN INH_NP ,_, as_RB well_RB as_IN the_DT concentration_NN of_IN INH_NP ,_, in_IN cultures_NNS containing_VBG representatives_NNS of_IN the_DT initially_RB INH-susceptible_JJ strains_NNS ,_, representatives_NNS from_IN cultures_NNS induced_VBN to_TO have_VB high_JJ levels_NNS of_IN resistance_NN to_TO INH_NP ,_, or_CC representatives_NNS from_IN cultures_NNS whose_WP$ progeny_NN had_VBD reverted_VBN in_IN drug-free_JJ medium_NN to_TO their_PP$ initial_JJ susceptibility_NN to_TO INH_NP are_VBP described_VBN in_IN the_DT figure_NN legends_NNS and_CC in_IN the_DT tables_NNS ,_, where_WRB appropriate_JJ ._SENT FIG._NN 2_CD ._SENT |_SYM Time_NP course_NN of_IN induced_VBN INH_NP resistance_NN and_CC reversion_NN of_IN the_DT H37Rv_NP (_( ATCC_NP 27294_CD )_) reference_NN strain_NN ._SENT Time_NN course_NN of_IN induced_VBN INH_NP resistance_NN and_CC reversion_NN of_IN the_DT H37Rv_NP (_( ATCC_NP 27294_CD )_) reference_NN strain_NN ._SENT Culture_NN of_IN INH-susceptible_JJ isolates_NNS (_( time_NN zero_CD ;_: MIC_NP ,_, 0.03_CD mg/liter_NN )_) in_IN INH-containing_NP medium_NN (_( 0.1_CD mg/liter_NN )_) incubated_VBN beyond_IN the_DT antibiotic_JJ susceptibility_NN assay_NN time_NN frame_NN (_( 4_CD to_TO 12_CD days_NNS )_) resulted_VBN in_IN evident_JJ growth_NN after_IN 28_CD days_NNS ._SENT The_DT ability_NN to_TO grow_VB in_IN 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN was_VBD confirmed_VBN ,_, the_DT MICs_NP were_VBD determined_VBN ,_, and_CC the_DT cells_NNS were_VBD designated_VBN as_IN having_VBG induced_VBN INH_NP resistance_NN (_( MIC_NP ,_, 0.2_CD mg/liter_NN )_) at_IN IL1_NP ._SENT These_DT cells_NNS were_VBD then_RB exposed_VBN to_TO INH_NP at_IN concentrations_NNS that_WDT corresponded_VBD to_TO the_DT MIC_NN for_IN the_DT previous_JJ passage_NN phase_NN ,_, and_CC after_IN 21_CD days_NNS the_DT growing_VBG cells_NNS were_VBD then_RB tested_VBN as_IN described_VBN above_IN and_CC the_DT cells_NNS were_VBD designated_VBN as_IN having_VBG induced_VBN INH_NP resistance_NN (_( MIC_NP ,_, 0.5_CD mg/liter_NN )_) at_IN IL2_NP ._SENT The_DT process_NN was_VBD continued_VBN to_TO IL7_JJ ,_, at_IN which_WDT time_NN the_DT cells_NNS were_VBD able_JJ to_TO grow_VB in_IN the_DT presence_NN of_IN 20_CD mg_NN of_IN INH_NP per_IN liter_NN (_( MIC_NP ,_, 40_CD mg/liter_NN )_) ._SENT Cells_NNS at_IN IL7_JJ were_VBD repeatedly_RB transferred_VBN to_TO drug-free_JJ medium_NN ._SENT The_DT MICs_NP were_VBD determined_VBN between_IN passages_NNS ,_, and_CC the_DT MICs_NP gradually_RB decreased_VBD (_( IL8_NP ,_, IL9_NP ,_, and_CC IL10_NP )_) ,_, reaching_VBG the_DT MIC_NN for_IN the_DT initial_JJ parent_NN strain_NN (_( 0.06_CD mg/liter_NN )_) at_IN IL11_NP ._SENT The_DT cells_NNS present_JJ in_IN the_DT culture_NN at_IN IL11_NP served_VBD as_IN a_DT source_NN for_IN the_DT repeat_NN cycle_NN of_IN induced_VBN resistance_NN to_TO INH_NP (_( data_NN not_RB shown_VBN )_) ._SENT Repetition_NN of_IN the_DT antibiotic_JJ susceptibility_NN assay_NN with_IN M._NP tuberculosis_NN H37Rv_NP (_( ATTC_NP 27294_CD )_) and_CC the_DT eight_CD clinical_JJ strains_NNS with_IN the_DT BACTEC_NP 460-TB_JJ system_NN indicated_VBD that_IN each_DT of_IN these_DT acid-fast-positive_JJ strains_NNS was_VBD susceptible_JJ to_TO 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN as_IN well_RB as_RB to_TO rifampin_NN ,_, streptomycin_NN ,_, and_CC ethambutol_NN ._SENT Extending_VBG the_DT incubation_NN period_NN for_IN INH-susceptible_JJ cultures_NNS in_IN INH-containing_JJ medium_NN beyond_IN the_DT completion_NN of_IN the_DT antibiotic_JJ susceptibility_NN assay_NN yielded_VBD evidence_NN of_IN visible_JJ growth_NN ._SENT By_IN the_DT end_NN of_IN 28_CD days_NNS after_IN the_DT beginning_NN of_IN the_DT INH_NP susceptibility_NN assay_NN ,_, the_DT growth_NN in_IN all_DT of_IN the_DT cultures_NNS with_IN initially_RB susceptible_JJ isolates_NNS reached_VBD a_DT level_NN comparable_JJ to_TO that_DT for_IN the_DT individual_JJ controls_NNS grown_VBN in_IN drug-free_JJ medium_NN ._SENT Direct_JJ examination_NN of_IN the_DT contents_NNS of_IN each_DT vial_NN by_IN the_DT use_NN of_IN identification_NN probes_NNS and_CC staining_VBG for_IN acid-fast_JJ bacilli_NNS indicated_VBD that_IN all_DT of_IN the_DT organisms_NNS were_VBD M._NP tuberculosis_NN ._SENT However_RB ,_, unlike_IN their_PP$ parents_NNS ,_, which_WDT were_VBD all_RB positive_JJ by_IN staining_VBG with_IN the_DT Ziehl-Neelsen_NP acid-fast_JJ stain_NN ,_, the_DT cells_NNS from_IN any_DT given_VBN INH-containing_NN vial_NN presented_VBN with_IN wide_JJ variations_NNS in_IN acid-fast_JJ staining_VBG ,_, ranging_VBG from_IN negative_JJ to_TO positive_JJ staining_VBG status_NN ._SENT This_DT variation_NN in_IN acid-fast_JJ staining_VBG is_VBZ probably_RB due_JJ to_TO some_DT inhibition_NN of_IN cell_NN wall_NN mycolic_JJ acid_NN synthesis_NN ._SENT Given_VBN that_DT INH_NP resistance_NN is_VBZ associated_VBN with_IN the_DT loss_NN of_IN catalase_NN activity_NN ,_, the_DT contents_NNS of_IN the_DT INH-containing_NP vials_NNS were_VBD tested_VBN for_IN this_DT biochemical_JJ characteristic_NN ._SENT All_DT retained_JJ catalase_NN activity_NN ._SENT The_DT possibility_NN that_IN the_DT potency_NN of_IN INH_NP in_IN the_DT vials_NNS had_VBD been_VBN affected_VBN by_IN prolonged_JJ incubation_NN was_VBD ruled_VBN out_RP since_IN the_DT medium_NN ,_, when_WRB filtered_VBN free_JJ of_IN cells_NNS ,_, was_VBD as_RB effective_JJ as_IN freshly_RB made_VBN INH-containing_JJ medium_NN against_IN M._NP tuberculosis_NN isolates_VBZ with_IN proven_JJ INH_NP susceptibility_NN ._SENT Inducement_NN of_IN INH_NP resistance_NN ._SENT |_SYM Once_RB the_DT possibility_NN of_IN contamination_NN and_CC the_DT possibility_NN that_IN the_DT INH-containing_NP medium_NN had_VBD reduced_VBN potency_NN were_VBD ruled_VBN out_RP ,_, aliquots_NNS of_IN each_DT of_IN the_DT cultures_NNS that_WDT were_VBD then_RB growing_VBG in_IN the_DT presence_NN of_IN INH_NP were_VBD subjected_VBN to_TO a_DT repeat_NN INH_NP susceptibility_NN assay_NN with_IN the_DT BACTEC_NP 460-TB_JJ system_NN and_CC solid_JJ medium_NN ._SENT Separate_JJ determinations_NNS of_IN the_DT MIC_NP of_IN INH_NP by_IN the_DT modified_JJ broth_NN radiometric_JJ method_NN yielded_VBD similar_JJ data_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT For_IN a_DT better_JJR understanding_NN of_IN the_DT INH_NP MICs_NP ,_, the_DT values_NNS presented_VBN in_IN the_DT text_NN and_CC tables_NNS refer_VBP only_RB to_TO the_DT INH_NP concentrations_NNS used_VBN with_IN the_DT modified_JJ broth_NN radiometric_JJ method_NN of_IN Lee_NP and_CC Heifets_NP (_( ;_: S._NP Siddiqi_NP ,_, BACTEC_NP TB_NN system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, Becton_NP Dickinson_NP Diagnostic_NP Instrument_NP Systems_NPS )_) ._SENT The_DT results_NNS presented_VBN in_IN Table_NP show_VBP that_IN at_IN the_DT first_JJ stage_NN of_IN resistance_NN to_TO INH_NP by_IN initially_RB INH-susceptible_JJ strains_NNS (_( induction_NN level_NN 1_CD [_SYM IL1_NP ]_SYM )_) these_DT organisms_NNS were_VBD indeed_RB resistant_JJ to_TO INH_NP (_( 0.1_CD mg/liter_NN )_) and_CC grew_VBD on_IN INH-containing_NP agar_NN (_( 0.2_CD mg/liter_NN )_) ._SENT The_DT MICs_NP of_IN INH_NP for_IN these_DT strains_NNS were_VBD much_RB higher_JJR than_IN those_DT for_IN the_DT parents_NNS used_VBN at_IN the_DT beginning_NN of_IN this_DT study_NN ._SENT Aliquots_NNS of_IN these_DT cultures_NNS with_IN INH-induced_JJ resistance_NN at_IN IL1_NP were_VBD transferred_VBN to_TO fresh_JJ BACTEC_NP 12B_JJ vials_NNS containing_VBG a_DT concentration_NN of_IN INH_NP that_WDT corresponded_VBD to_TO the_DT new_JJ MIC_NN (_( 0.2_CD mg/liter_NN )_) ._SENT These_DT cultures_NNS reached_VBD full_JJ growth_NN by_IN the_DT end_NN of_IN 10_CD to_TO 21_CD days_NNS and_CC were_VBD subjected_VBN to_TO INH_NP MIC_NP determination_NN ,_, after_IN which_WDT time_NN they_PP served_VBD as_IN sources_NNS for_IN the_DT next_JJ passage_NN in_IN medium_NN containing_VBG a_DT concentration_NN of_IN INH_NP that_WDT corresponded_VBD to_TO that_DT which_WDT was_VBD shown_VBN to_TO be_VB the_DT new_JJ INH_NP MIC_NP for_IN the_DT strains_NNS in_IN the_DT previous_JJ passage_NN ._SENT These_DT organisms_NNS ,_, referred_VBD to_TO as_IN isolates_NNS with_IN INH-induced_JJ resistance_NN at_IN the_DT second_JJ induction_NN level_NN (_( IL2_NP )_) ,_, were_VBD assayed_VBN for_IN determination_NN of_IN the_DT INH_NP MIC_NP (_( the_DT INH_NP MIC_NP at_IN IL2_NP was_VBD then_RB 0.5_CD mg/liter_NN )_) and_CC were_VBD used_VBN as_IN sources_NNS for_IN five_CD additional_JJ serial_JJ passages_NNS ,_, with_IN each_DT succeeding_VBG passage_NN containing_VBG a_DT concentration_NN of_IN INH_NP that_WDT corresponded_VBD to_TO the_DT previous_JJ MIC_NN for_IN the_DT strain_NN with_IN INH-induced_JJ resistance_NN at_IN IL2_NP ,_, IL3_NP ,_, IL4_NP ,_, IL5_NP ,_, IL6_NP ,_, and_CC IL7_JJ ._SENT These_DT passages_NNS were_VBD also_RB conducted_VBN with_IN solid_JJ medium_NN containing_VBG equivalent_JJ concentrations_NNS of_IN INH_NP ,_, and_CC the_DT plates_NNS were_VBD evaluated_VBN for_IN the_DT numbers_NNS of_IN CFU_NP ._SENT Figure_NN describes_VBZ the_DT increases_NNS in_IN the_DT INH_NP MICs_NP for_IN each_DT of_IN the_DT induction_NN levels_NNS when_WRB the_DT ATCC_NP strain_NN was_VBD subjected_VBN to_TO stepwise_JJ increases_NNS in_IN the_DT concentrations_NNS of_IN INH_NP ,_, as_RB described_VBN above_IN ._SENT This_DT procedure_NN yielded_VBD M._NP tuberculosis_NN isolates_NNS that_WDT were_VBD capable_JJ of_IN growing_VBG in_IN liquid_JJ or_CC solid_JJ medium_NN containing_VBG 20.0_CD mg_NN of_IN INH_NP per_IN liter_NN ._SENT All_DT eight_CD clinical_JJ strains_NNS were_VBD subjected_VBN to_TO the_DT same_JJ procedures_NNS used_VBN for_IN the_DT induction_NN of_IN high-level_JJ resistance_NN to_TO INH_NP ,_, and_CC similar_JJ results_NNS were_VBD obtained_VBN ,_, with_IN little_JJ difference_NN in_IN the_DT amount_NN of_IN time_NN required_VBN for_IN the_DT manifestation_NN of_IN induced_VBN resistance_NN at_IN each_DT sequential_JJ level_NN of_IN induced_VBN resistance_NN being_VBG detected_VBN (_( data_NNS not_RB shown_VBN due_JJ to_TO limitation_NN of_IN space_NN )_) ._SENT Reversal_NN of_IN INH_NP resistance_NN ._SENT |_SYM Although_IN the_DT contents_NNS of_IN each_DT culture_NN at_IN the_DT conclusion_NN of_IN each_DT passage_NN phase_NN were_VBD shown_VBN by_IN the_DT use_NN of_IN identification_NN probes_NNS to_TO be_VB M._NP tuberculosis_NN ,_, there_EX was_VBD the_DT real_JJ possibility_NN that_IN the_DT increasing_VBG level_NN of_IN resistance_NN to_TO INH_NP was_VBD due_JJ to_TO the_DT selection_NN of_IN mutants_NNS containing_VBG any_DT one_CD of_IN the_DT known_VBN mutations_NNS associated_VBN with_IN resistance_NN to_TO INH_NP ._SENT Since_IN mutations_NNS remain_VBP true_JJ when_WRB the_DT isolates_NNS are_VBP transferred_VBN to_TO drug-free_JJ medium_NN ,_, aliquots_NNS were_VBD taken_VBN from_IN cultures_NNS of_IN isolates_NNS that_WDT were_VBD growing_VBG in_IN 20.0_CD mg_NN of_IN INH_NP per_IN liter_NN (_( induced_VBN resistance_NN to_TO INH_NP at_IN IL7_JJ )_) and_CC transferred_VBN to_TO drug-free_JJ medium_NN ,_, after_IN which_WDT time_NN serial_NN passages_NNS were_VBD conducted_VBN in_IN drug-free_JJ medium_NN ._SENT Between_IN serial_JJ passages_NNS ,_, an_DT assay_NN for_IN determination_NN of_IN the_DT INH_NP MIC_NP was_VBD conducted_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT MICs_NN for_IN isolates_NNS from_IN each_DT successive_JJ passage_NN (_( IL8_NP ,_, IL9_NP ,_, and_CC IL10_NP )_) continued_VBD to_TO decrease_VB ,_, eventually_RB reaching_VBG that_IN for_IN the_DT initial_JJ parent_NN strain_NN (_( average_JJ MIC_NN at_IN IL11_NP ,_, 0.06_CD mg/liter_NN )_) ._SENT The_DT latter_JJ progeny_NN that_IN by_IN this_DT time_NN were_VBD fully_RB INH_NP susceptible_JJ were_VBD subjected_VBN to_TO prolonged_JJ incubation_NN in_IN INH_NP ,_, as_RB were_VBD their_PP$ original_JJ parents_NNS ,_, and_CC the_DT cycle_NN of_IN induced_VBN resistance_NN to_TO INH_NP was_VBD again_RB successfully_RB repeated_VBN ._SENT The_DT induction_NN of_IN INH_NP resistance_NN and_CC its_PP$ reversibility_NN with_IN repeated_JJ passage_NN in_IN drug-free_JJ medium_NN ,_, followed_VBN by_IN the_DT repeat_NN of_IN the_DT INH_NP resistance_NN induction_NN cycle_NN ,_, argue_VBP against_IN the_DT involvement_NN of_IN any_DT chromosomal_JJ mutation_NN that_WDT may_MD have_VB been_VBN selected_VBN or_CC the_DT introduction_NN of_IN a_DT contaminant_NN during_IN the_DT manipulations_NNS described_VBD above_IN ._SENT Nevertheless_RB ,_, to_TO eliminate_VB these_DT two_CD possibilities_NNS ,_, the_DT probability_NN of_IN which_WDT are_VBP low_JJ ,_, representative_JJ strains_NNS from_IN each_DT phase_NN of_IN the_DT cycle_NN (_( susceptible_JJ strains_NNS and_CC strains_NNS with_IN induced_VBN resistance_NN )_) were_VBD subjected_VBN to_TO IS6110-RFLP_NP analysis_NN and_CC katG_NN mutation_NN identification_NN analysis_NN ._SENT The_DT IS6110-RFLP_NP pattern_NN remained_VBD identical_JJ for_IN each_DT representative_NN throughout_IN the_DT cycle_NN ,_, thus_RB eliminating_VBG any_DT chance_NN that_IN the_DT appearance_NN of_IN an_DT increased_VBN level_NN of_IN resistance_NN was_VBD due_JJ to_TO the_DT introduction_NN of_IN a_DT contaminant_NN or_CC to_TO the_DT testing_NN of_IN a_DT specimen_NN of_IN a_DT mixed_JJ type_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT appearance_NN of_IN INH_NP resistance_NN is_VBZ not_RB due_JJ to_TO the_DT selection_NN of_IN katG_NN mutants_NNS ,_, which_WDT are_VBP known_VBN to_TO be_VB the_DT most_RBS prevalently_RB associated_VBN with_IN high-level_JJ resistance_NN to_TO INH_NP as_IN a_DT result_NN of_IN the_DT S315->T_NP mutation_NN ,_, since_IN all_DT of_IN the_DT PCR-RFLP_NP analyses_NNS that_WDT detect_VBP this_DT point_NN mutation_NN were_VBD negative_JJ for_IN all_DT strains_NNS tested_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Reduction_NN of_IN levels_NNS of_IN INH_NP resistance_NN by_IN an_DT efflux_NN pump_NN inhibitor_NN ._SENT |_SYM The_DT induction_NN of_IN high-level_JJ resistance_NN to_TO INH_NP may_MD be_VB due_JJ to_TO the_DT activation_NN or_CC induction_NN of_IN an_DT efflux_NN pump_NN mechanism(s_NNS )_) ._SENT For_IN this_DT purpose_NN INH-susceptible_JJ reference_NN strain_NN M._NP tuberculosis_NN H37Rv_NP (_( ATCC_NP 27294_CD )_) and_CC isolates_VBZ with_IN INH-induced_JJ resistance_NN at_IN IL7_JJ (_( resistant_JJ to_TO INH_NP at_IN 20.0_CD mg/liter_NN [_SYM MIC_JJ ,_, 40_CD mg/liter_NN ]_SYM )_) were_VBD evaluated_VBN for_IN the_DT presence_NN of_IN an_DT efflux_NN pump_NN by_IN the_DT use_NN of_IN known_VBN inhibitors_NNS of_IN bacterial_JJ efflux_NN pumps_NNS such_JJ as_IN CPZ_NP ,_, verapamil_NN ,_, and_CC reserpine_NN ._SENT The_DT existence_NN of_IN an_DT efflux_NN pump_NN that_WDT renders_VBZ a_DT bacterium_NN resistant_JJ to_TO a_DT given_VBN antibiotic_NN is_VBZ shown_VBN by_IN the_DT ability_NN of_IN known_VBN inhibitors_NNS of_IN efflux_NN pumps_NNS to_TO reduce_VB the_DT level_NN of_IN resistance_NN to_TO the_DT antibiotic_NN ._SENT The_DT concentration_NN selected_VBN for_IN an_DT inhibitor_NN of_IN an_DT efflux_NN pump_NN must_MD be_VB one_CD that_WDT has_VBZ a_DT nominal_JJ effect_NN on_IN the_DT growth_NN of_IN the_DT bacterium_NN itself_PP so_RB that_IN the_DT effects_NNS related_VBN to_TO the_DT action_NN of_IN the_DT pump_NN on_IN the_DT activity_NN of_IN a_DT given_VBN antibiotic_NN can_MD be_VB isolated_VBN ._SENT Table_NN identifies_VBZ the_DT highest_JJS concentrations_NNS of_IN CPZ_NP ,_, verapamil_NN ,_, and_CC reserpine_NN that_WDT had_VBD no_DT effect_NN on_IN the_DT initial_JJ INH-susceptible_JJ ATCC_NP 27294_CD reference_NN strain_NN and_CC the_DT clinical_JJ strains_NNS used_VBN in_IN this_DT study_NN ,_, as_RB well_RB as_IN the_DT concentrations_NNS that_WDT correspond_VBP to_TO their_PP$ MICs_NNS ._SENT Whereas_IN subinhibitory_JJ concentrations_NNS of_IN CPZ_NP or_CC verapamil_NP did_VBD not_RB affect_VB the_DT ability_NN of_IN the_DT cells_NNS with_IN induced_VBN INH_NP resistance_NN at_IN IL7_JJ to_TO grow_VB in_IN the_DT presence_NN of_IN 20_CD mg_NN of_IN INH_NP per_IN liter_NN (_( data_NNS not_RB shown_VBN )_) ,_, reserpine_NN at_IN 20_CD mg/liter_NN reduced_VBD the_DT ability_NN of_IN all_DT of_IN the_DT strains_NNS at_IN IL7_JJ to_TO grow_VB in_IN the_DT presence_NN of_IN 20.0_CD to_TO 0.2_CD mg_NN of_IN INH_NP liter_NN ._SENT Complete_JJ inhibition_NN of_IN the_DT growth_NN of_IN strains_NNS with_IN induced_VBN INH_NP resistance_NN at_IN IL7_JJ in_IN the_DT presence_NN of_IN 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN required_VBD an_DT average_JJ reserpine_NN concentration_NN of_IN 40_CD mg/liter_NN ._SENT However_RB ,_, although_IN this_DT concentration_NN of_IN reserpine_NN alone_RB had_VBD no_DT effect_NN on_IN the_DT growth_NN of_IN the_DT initial_JJ INH-susceptible_JJ strains_NNS ,_, it_PP did_VBD inhibit_VB the_DT growth_NN of_IN these_DT cells_NNS with_IN induced_VBN INH_NP resistance_NN by_IN as_RB much_JJ as_IN 15_CD %_NN ,_, an_DT effect_NN which_WDT we_PP deemed_VBD the_DT nominal_JJ effect_NN ._SENT The_DT data_NNS presented_VBN in_IN Table_NP also_RB show_VBP that_IN when_WRB strains_NNS with_IN induced_VBN resistance_NN to_TO INH_NP at_IN 20_CD mg/liter_NN (_( IL7_JJ )_) were_VBD grown_VBN in_IN the_DT presence_NN of_IN reserpine_NN at_IN 20_CD mg/liter_NN and_CC INH_NP at_IN 0.1_CD and_CC 0.2_CD mg/liter_NN (_( with_IN the_DT 0.1-mg/liter_NN concentration_NN being_VBG the_DT critical_JJ concentration_NN of_IN INH_NP used_VBN as_IN the_DT cutoff_NN for_IN the_DT demonstration_NN of_IN resistance_NN of_IN a_DT clinical_JJ specimen_NN )_) ,_, their_PP$ growth_NN was_VBD not_RB completely_RB inhibited_VBN ._SENT This_DT apparent_JJ resistance_NN may_MD reflect_VB the_DT large_JJ number_NN of_IN efflux_NN pump_NN units_NNS that_WDT have_VBP been_VBN induced_VBN ,_, with_IN the_DT inhibitory_JJ capability_NN of_IN INH_NP overcome_VBN by_IN this_DT concentration_NN of_IN reserpine_NN ._SENT This_DT interpretation_NN receives_VBZ support_NN from_IN the_DT data_NNS also_RB presented_VBN in_IN Table_NP ,_, which_WDT demonstrate_VBP that_IN an_DT increase_NN in_IN the_DT concentration_NN of_IN reserpine_NN to_TO 40_CD mg/liter_NN practically_RB eliminates_VBZ resistance_NN to_TO INH_NP ._SENT It_PP may_MD be_VB noted_VBN from_IN the_DT data_NNS in_IN Table_NP that_IN strains_NNS that_WDT reverted_VBD to_TO INH_NP susceptibility_NN had_VBD some_DT demonstrable_JJ resistance_NN to_TO concentrations_NNS of_IN INH_NP that_WDT were_VBD slightly_RB above_IN and_CC at_IN the_DT cutoff_NN point_NN used_VBN for_IN the_DT interpretation_NN of_IN resistance_NN to_TO INH_NP ._SENT We_PP interpret_VBP these_DT results_NNS to_TO indicate_VB that_IN even_RB after_IN extensive_JJ culture_NN in_IN drug-free_JJ medium_NN ,_, there_EX is_VBZ still_RB evidence_NN of_IN a_DT reserpine-sensitive_JJ mechanism_NN which_WDT is_VBZ completely_RB inhibited_VBN only_RB by_IN the_DT higher_JJR concentration_NN of_IN reserpine_NN (_( 40_CD mg/liter_NN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Appearance_NP of_IN INH_NP resistance_NN after_IN completion_NN of_IN INH_NP susceptibility_NN assay_NN ._SENT Appearance_NN of_IN INH_NP resistance_NN after_IN completion_NN of_IN INH_NP susceptibility_NN assay_NN ._SENT The_DT growth_NN curves_VBZ of_IN the_DT H37Rv_NP (_( ATCC_NP 27294_CD )_) reference_NN strain_NN (_( *_SYM )_) and_CC the_DT eight_CD clinical_JJ INH-susceptible_JJ strains_NNS in_IN BACTEC_NP 12B_NP vials_NNS containing_VBG 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN and_CC the_DT H37Rv_NP (_( ATCC_NP 27294_CD )_) reference_NN strain_NN and_CC the_DT eight_CD clinical_JJ INH-susceptible_JJ strains_NNS grown_VBN in_IN drug-free_JJ medium_NN as_IN controls_NNS are_VBP shown_VBN ._SENT The_DT results_NNS for_IN the_DT eight_CD clinical_JJ strains_NNS are_VBP recorded_VBN at_IN 5-day_JJ intervals_NNS ,_, with_IN each_DT point_NN being_VBG the_DT mean_JJ +-_NN standard_JJ deviation_NN of_IN the_DT daily_JJ readings_NNS ._SENT All_DT strains_NNS were_VBD initially_RB susceptible_JJ to_TO 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN ,_, as_RB evidenced_VBN by_IN the_DT results_NNS at_IN the_DT end_NN of_IN the_DT INH_NP susceptibility_NN assay_NN period_NN (_( maximum_JJ ,_, 12_CD days_NNS )_) ._SENT Incubation_NN for_IN a_DT maximum_NN of_IN an_DT additional_JJ 28_CD days_NNS yielded_VBD a_DT growth_NN index_NN that_WDT was_VBD indicative_JJ of_IN resistance_NN to_TO INH_NP ._SENT TABLE_NN 1_CD |_SYM Characteristics_NN of_IN contents_NNS of_IN INH-containing_NP BACTEC_NP 12B_NP vials_NNS TABLE_NP 2_CD |_SYM Highest_JJ concentrations_NNS of_IN CPZ_NP ,_, verapamil_NN ,_, and_CC reserpine_NN with_IN nominal_JJ effects_NNS on_IN growth_NN of_IN M._NP tuberculosis_NN parental_JJ strains_NNS (_( INH_NP susceptible_JJ )_) and_CC the_DT MICs_NN for_IN complete_JJ inhibition_NN of_IN growth_NN TABLE_NP 3_CD |_SYM Effect_NN of_IN a_DT known_VBN inhibitor_NN of_IN efflux_NN pumps_NNS ,_, reserpine_NN ,_, on_IN activities_NNS of_IN INH_NP on_IN INH-susceptible_JJ strains_NNS ,_, strains_NNS at_IN IL7_JJ with_IN induced_VBN INH_NP resistance_NN ,_, and_CC INH-susceptible_JJ revertants_NNS at_IN IL11a_NP Considerable_JJ variation_NN in_IN antibiotic_JJ susceptibility_NN is_VBZ found_VBN among_IN the_DT different_JJ species_NN of_IN mycobacteria_NNS ,_, such_JJ that_IN whereas_IN M._NP tuberculosis_NN is_VBZ highly_RB susceptible_JJ to_TO INH_NP ,_, M._NP smegmatis_NN and_CC other_JJ fast-growing_JJ mycobacteria_NNS are_VBP resistant_JJ to_TO the_DT drug_NN ._SENT The_DT susceptibility_NN of_IN M._NP tuberculosis_NN to_TO INH_NP is_VBZ due_JJ to_TO an_DT efficient_JJ conversion_NN of_IN the_DT drug_NN INH_NP by_IN the_DT catalase-peroxidase_NN enzyme_NN to_TO a_DT compound_NN that_WDT inhibits_VBZ mycolic_JJ acid_JJ synthesis_NN ._SENT Recently_RB ,_, natural_JJ resistance_NN of_IN M._NP smegmatis_NN to_TO INH_NP has_VBZ also_RB been_VBN ascribed_VBN to_TO a_DT verapamil-_NN and_CC reserpine-sensitive_JJ efflux_NN pump_NN ._SENT The_DT observations_NNS made_VBN from_IN our_PP$ study_NN indicate_VBP for_IN the_DT first_JJ time_NN that_IN INH-susceptible_JJ strains_NNS of_IN M._NP tuberculosis_NN exposed_VBN to_TO INH_NP for_IN a_DT prolonged_JJ period_NN of_IN time_NN can_MD become_VB resistant_NN to_TO 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN ._SENT This_DT induced_VBN resistance_NN to_TO INH_NP is_VBZ reproducible_JJ and_CC can_MD gradually_RB be_VB increased_VBN to_TO 20_CD mg/liter_NN by_IN gradual_JJ stepwise_JJ increases_NNS in_IN the_DT concentration_NN of_IN INH_NP ._SENT Induced_VBN resistance_NN can_MD be_VB effectively_RB reversed_VBN by_IN consecutive_JJ passage_NN in_IN drug-free_JJ medium_NN ._SENT The_DT cycle_NN of_IN induced_VBN resistance_NN to_TO INH_NP can_MD be_VB repeated_VBN by_IN these_DT procedures_NNS ,_, probably_RB ad_NN infinitum_NN ._SENT The_DT use_NN of_IN identification_NN probes_NNS and_CC IS6110-RFLP_NN analysis_NN ruled_VBD out_RP any_DT possibility_NN that_IN a_DT contaminant_NN was_VBD present_JJ or_CC that_IN the_DT initial_JJ specimen_NN was_VBD of_IN a_DT mixed_JJ type_NN ._SENT The_DT reversal_NN of_IN induced_VBN resistance_NN to_TO INH_NP by_IN simple_JJ serial_JJ passage_NN in_IN drug-free_JJ medium_NN ruled_VBD out_RP the_DT possibility_NN of_IN selection_NN of_IN INH_NP resistance_NN mutations_NNS that_WDT could_MD account_VB for_IN the_DT INH_NP resistance_NN ._SENT Direct_JJ evaluation_NN of_IN the_DT cultures_NNS at_IN each_DT phase_NN of_IN the_DT study_NN for_IN the_DT presence_NN of_IN katG_NN mutations_NNS further_RBR supported_VBD the_DT contention_NN that_IN the_DT induction_NN of_IN resistance_NN to_TO INH_NP was_VBD not_RB due_JJ to_TO the_DT selection_NN of_IN mutations_NNS most_RBS commonly_RB associated_VBN with_IN resistance_NN to_TO INH_NP ._SENT Lastly_RB ,_, although_IN gene_NN amplification_NN can_MD cause_VB increased_VBN levels_NNS of_IN antibiotic_JJ resistance_NN in_IN other_JJ species_NNS of_IN bacteria_NNS by_IN overproduction_NN of_IN an_DT antibiotic-inactivating_JJ enzyme_NN ,_, it_PP is_VBZ unlikely_JJ that_IN the_DT high-level_JJ resistance_NN to_TO INH_NP induced_VBN in_IN this_DT study_NN is_VBZ caused_VBN by_IN a_DT similar_JJ mechanism_NN ,_, inasmuch_RB as_IN the_DT resistance_NN observed_VBD in_IN our_PP$ study_NN continues_VBZ while_IN the_DT organism_NN is_VBZ replicating_VBG in_IN the_DT presence_NN of_IN high_JJ levels_NNS of_IN INH_NP ._SENT The_DT loss_NN of_IN this_DT resistance_NN requires_VBZ a_DT large_JJ number_NN of_IN replications_NNS afforded_VBN by_IN five_CD prolonged_JJ passages_NNS in_IN drug-free_JJ medium_NN ,_, whereas_IN antibiotic_JJ resistance_NN due_JJ to_TO gene_NN amplification_NN is_VBZ much_RB more_RBR rapidly_RB lost_VBN ._SENT In_IN addition_NN ,_, gene_NN amplification_NN has_VBZ not_RB been_VBN observed_VBN with_IN M._NP tuberculosis_NN due_JJ to_TO the_DT high_JJ degree_NN of_IN inherent_JJ stability_NN of_IN the_DT chromosome_NN ._SENT As_IN mentioned_VBN in_IN the_DT introduction_NN ,_, the_DT INH_NP resistance_NN in_IN only_RB about_RB 70_CD to_TO 80_CD %_NN of_IN M._NP tuberculosis_NN strains_NNS has_VBZ been_VBN correlated_VBN to_TO mutations_NNS in_IN any_DT of_IN the_DT genes_NNS assigned_VBN as_IN potential_JJ targets_NNS or_CC to_TO alternative_JJ metabolic_JJ pathways_NNS for_IN INH_NP inhibition_NN ._SENT Efflux_NN pumps_NNS that_WDT render_VBP bacteria_NNS resistant_JJ to_TO antibiotics_NNS have_VBP been_VBN identified_VBN in_IN all_DT bacteria_NNS ,_, including_VBG mycobacteria_NNS ,_, studied_VBN to_TO date_NN ._SENT The_DT correlation_NN of_IN antibiotic_JJ resistance_NN to_TO an_DT efflux_NN pump_NN is_VBZ made_VBN when_WRB the_DT level_NN of_IN antibiotic_JJ resistance_NN is_VBZ reduced_VBN in_IN the_DT presence_NN of_IN both_DT antibiotic_NN and_CC an_DT inhibitor_NN of_IN the_DT pump_NN itself_PP ._SENT Without_IN exception_NN ,_, each_DT of_IN the_DT studies_NNS cited_VBD evaluated_VBN the_DT organisms_NNS for_IN the_DT presence_NN of_IN a_DT preexisting_VBG efflux_NN pump_NN ._SENT Accordingly_RB ,_, strains_NNS of_IN M._NP tuberculosis_NN that_WDT are_VBP susceptible_JJ to_TO INH_NP would_MD by_IN definition_NN not_RB contain_VBP a_DT mutation_NN for_IN INH_NP resistance_NN ,_, nor_CC would_MD they_PP be_VB expected_VBN to_TO harbor_VB an_DT efflux_NN pump_NN capable_JJ of_IN pumping_VBG out_RP INH_NP ._SENT The_DT demonstration_NN in_IN our_PP$ study_NN that_IN high-level_JJ resistance_NN to_TO INH_NP can_MD be_VB gradually_RB induced_VBN in_IN INH-susceptible_JJ strains_NNS of_IN M._NP tuberculosis_NN via_IN a_DT mechanism_NN that_WDT does_VBZ not_RB involve_VB a_DT mutation_NN but_CC that_DT is_VBZ sensitive_JJ to_TO reserpine_NN supports_VBZ the_DT contention_NN that_WDT induced_VBD resistance_NN might_MD be_VB due_JJ to_TO an_DT efflux_NN pump_NN mechanism_NN ._SENT Whether_IN induced_VBN resistance_NN is_VBZ due_JJ to_TO activation_NN of_IN a_DT preexisting_VBG efflux_NN pump_NN ,_, an_DT increase_NN in_IN the_DT number_NN of_IN efflux_NN pump_NN units_NNS ,_, or_CC de_NP novo_NP synthesis_NN of_IN the_DT pump_NN itself_PP was_VBD not_RB determined_VBN in_IN the_DT present_JJ study_NN ._SENT The_DT growth_NN inhibition_NN results_NNS obtained_VBN by_IN the_DT use_NN of_IN the_DT lower_JJR concentration_NN of_IN reserpine_NN (_( 20_CD mg/liter_NN )_) in_IN combination_NN with_IN 0.2_CD or_CC 0.1_CD mg_NN of_IN INH_NP per_IN liter_NN with_IN strains_NNS obtained_VBN at_IN IL11_JJ (_( INH-susceptible_JJ revertant_JJ strains_NNS )_) ,_, although_IN consistent_JJ with_IN the_DT presence_NN of_IN an_DT efflux_NN pump_NN mechanism_NN ,_, are_VBP difficult_JJ to_TO interpret_VB ,_, inasmuch_RB as_IN the_DT growth_NN of_IN these_DT strains_NNS should_MD be_VB fully_RB inhibited_VBN ._SENT Although_IN it_PP is_VBZ possible_JJ that_IN the_DT induced_VBN resistance_NN to_TO INH_NP in_IN our_PP$ study_NN was_VBD due_JJ to_TO the_DT selection_NN of_IN mutants_NNS capable_JJ of_IN synthesizing_VBG an_DT efflux_NN pump_NN ,_, we_PP consider_VBP this_DT possibility_NN remote_JJ ,_, inasmuch_RB as_IN the_DT ATCC_NP control_NN strain_NN and_CC all_DT eight_CD clinical_JJ strains_NNS were_VBD induced_VBN to_TO present_VB the_DT efflux_NN pump_NN ._SENT The_DT induction_NN of_IN high-level_JJ resistance_NN to_TO INH_NP by_IN continuous_JJ exposure_NN to_TO increasing_VBG concentrations_NNS of_IN the_DT antibiotic_NN has_VBZ not_RB been_VBN described_VBN previously_RB ._SENT The_DT induction_NN of_IN INH_NP resistance_NN by_IN INH_NP may_MD occur_VB during_IN INH_NP therapy_NN and_CC may_MD account_VB for_IN the_DT remainder_NN of_IN the_DT INH_NP resistance_NN that_WDT is_VBZ not_RB accounted_VBN for_IN by_IN mutations_NNS and_CC that_IN ,_, due_JJ to_TO the_DT limitation_NN of_IN the_DT time_NN interval_NN used_VBN for_IN the_DT INH_NP susceptibility_NN assay_NN ,_, is_VBZ not_RB detected_VBN ._SENT 